Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC‐TIVE study, an Italian nationwide survey

To investigate the prevalence of amyloid cardiomyopathy (AC) and the diagnostic accuracy of echocardiographic red flags of AC among consecutive adult patients undergoing transthoracic echocardiogram for reason other than AC in 13 Italian institutions.

[1]  G. Sinagra,et al.  Incidence and Characterization of Concealed Cardiac Amyloidosis Among Unselected Elderly Patients Undergoing Post-mortem Examination , 2021, Frontiers in Cardiovascular Medicine.

[2]  G. Barbati,et al.  Prognostic significance of unexplained left ventricular hypertrophy in patients undergoing carpal tunnel surgery , 2021, ESC heart failure.

[3]  S. Takashio,et al.  Sex-related differences in the clinical characteristics of wild-type transthyretin amyloidosis cardiomyopathy. , 2021, Journal of cardiology.

[4]  G. Parati,et al.  A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization-the first insight from the AC-TIVE Study. , 2021, European journal of preventive cardiology.

[5]  C. Autore,et al.  Yield of bone scintigraphy screening for transthyretin‐related cardiac amyloidosis in different conditions: Methodological issues and clinical implications , 2021, European journal of clinical investigation.

[6]  M. Beksac,et al.  Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. , 2021, The New England journal of medicine.

[7]  A. Masri,et al.  Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review , 2021, Cardiology and Therapy.

[8]  U. Eriksson,et al.  Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. , 2021, European heart journal.

[9]  M. Anselmino,et al.  The prevalence of TTR cardiac amyloidosis among patients undergoing bone scintigraphy , 2021, Journal of Nuclear Cardiology.

[10]  I. Porto,et al.  Prevalence of transthyretin amyloid cardiomyopathy in male patients who underwent bilateral carpal tunnel surgery: The ACTUAL study. , 2020, International journal of cardiology.

[11]  M. Emdin,et al.  A simple echocardiographic score to rule out cardiac amyloidosis , 2020, European journal of clinical investigation.

[12]  C. Rapezzi,et al.  Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery , 2020, European Journal of Internal Medicine.

[13]  P. Hansen,et al.  [Transthyretin amyloid cardiomyopathy]. , 2020, Ugeskrift for laeger.

[14]  M. Emdin,et al.  Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings , 2020, European journal of preventive cardiology.

[15]  G. Parati,et al.  Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. , 2020, International journal of cardiology.

[16]  G. Pontone,et al.  Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. , 2019, JACC. Cardiovascular imaging.

[17]  C. Rapezzi,et al.  Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. , 2019, Circulation. Heart failure.

[18]  F. Dominici,et al.  Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. , 2019, Circulation. Heart failure.

[19]  C. Rapezzi,et al.  Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS) , 2019, European heart journal.

[20]  Sanjiv J. Shah,et al.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.

[21]  M. Leon,et al.  Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement , 2017, European heart journal.

[22]  James C Moon,et al.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.

[23]  E. González-López,et al.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.

[24]  F. Salvi,et al.  Cardiac amyloidosis: the great pretender , 2015, Heart Failure Reviews.

[25]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.

[26]  G. Pedrizzetti,et al.  Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[27]  W. Edwards,et al.  Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. , 2014, JACC. Heart failure.

[28]  P. Hawkins,et al.  Systemic Amyloidosis in England: an epidemiological study , 2013, British journal of haematology.

[29]  P. L. Bergsagel,et al.  Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. , 2012, Blood.